ロード中...
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
Patients with highly active relapsing-remitting multiple sclerosis (RRMS) are at greater risk for disease progression and may respond differently to MS therapeutics than those with less active disease. The current post hoc analysis evaluated the effects of daclizumab high-yield process (DAC HYP) vs....
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Berlin Heidelberg
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3915085/ https://ncbi.nlm.nih.gov/pubmed/24375015 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00415-013-7196-4 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|